Putting The Brakes On The Immune Response
This article was originally published in Start Up
Known for its anti-coagulant properties, Protein S, which is found in circulation and expressed in activated T cells, also activates a molecular braking mechanism that prevents the immune response from going into overdrive, according to new research. As such, it could offer up a new target for treating inflammatory disorders.
You may also be interested in...
Both providers and users of digital pathology are confident that clinical use cases and the evidence needed to assure payers and encourage investment by commercial labs will overcome challenges around access and adoption.
Pharma companies are applying digital pathology throughout their research and development functions. Where are they now finding value?
Despite all of the buzz around adoption of digital health tools and whopping VC investments in consumer-facing digital health firms, pharma has yet to articulate a business model for co-development or integration of behavior-modifying digital therapeutics into their portfolios.